Quantum Biopharma Investors Class Action Notice

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Feb 17 2026

0mins

QNTM-16.67%

Should l Buy QNTM?

Source: Globenewswire

Class Action Notice: Quantum Biopharma, Ltd. is facing a class action lawsuit for securities transactions between January 6, 2021, and October 15, 2025, with investors required to file a lead plaintiff motion by February 23, 2026, to protect their legal rights.
False Trading Allegations: The complaint alleges that defendants engaged in thousands of spoofed sell orders during the class period, creating a false appearance of declining stock prices, which led investors to sell their shares at artificially depressed prices, resulting in improper losses.
Market Manipulation: Defendants profited from the scheme by purchasing Quantum shares at artificially deflated levels after driving the market price down, demonstrating misconduct that improperly induced investors to sell their shares.
Legal Assistance Offered: The Portnoy Law Firm provides complimentary case evaluations for affected investors, emphasizing their commitment to helping recover losses caused by corporate wrongdoing and protecting investor rights.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy QNTM?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on QNTM

About QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Class Action Filed Against Quantum Biopharma Shareholders

Feb 20 2026PRnewswire

Class Action Initiation: Pomerantz LLP has announced a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging that the company and certain executives engaged in securities fraud and other unlawful business practices, potentially causing significant losses for investors.
Manipulative Trading Allegations: The complaint accuses financial institutions like CIBC and RBC of entering thousands of spoofed sell orders to create a false impression of Quantum's stock price decline, deceiving other investors into selling their shares at artificially low prices, thus allowing the defendants to profit.
Investor Rights Protection: Investors are advised to apply by February 23, 2026, to become Lead Plaintiff in the class action if they purchased Quantum securities during the class period, thereby protecting their rights and participating in potential compensation.
Law Firm Credentials: Pomerantz LLP is a prominent firm in corporate and securities class litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, having recovered millions in damages for class members historically.

CIBC and RBC Accused of Manipulating Quantum Stock Prices

Feb 19 2026Globenewswire

Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades that artificially deflated the price of Quantum Biopharma Ltd. (NASDAQ: QNTM), impacting numerous investors' interests.
False Trading Practices: The complaint alleges that throughout the class period, the defendants placed thousands of spoofed sell orders to create a false appearance of declining stock prices, misleading investors into selling their shares at depressed prices, resulting in significant losses.
Damages Recovery: The lawsuit seeks damages on behalf of all investors who sold Quantum securities between January 6, 2021, and October 15, 2025, encouraging affected investors to apply as lead plaintiffs by February 23, 2026, to participate in potential recovery.
Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors nationwide, highlighting its crucial role in upholding market integrity.